MEDIOCON INC – Lapatinib is a synthetic 4-anilinoquinazoline tyrosine kinase inhibitor that selectively inhibits the intracellular kinase domains of human epidermal growth factor receptor (EGFR/HER1) and human epidermal growth factor receptor 2 (HER2/ErbB2). It is an established oncology pharmaceutical active ingredient.
Lapatinib is a small-molecule kinase inhibitor belonging to the 4-anilinoquinazoline class. It inhibits phosphorylation of EGFR and HER2 receptor tyrosine kinases, interfering with signaling pathways involved in tumor-cell proliferation and survival.
The pharmaceutical product lapatinib is supplied as the ditosylate monohydrate salt; however, the active parent compound Lapatinib has the chemical identity CAS 231277-92-2, molecular formula C₂₉H₂₆ClFN₄O₄S and molecular weight approximately 581.1 g/mol.
Product Name: Lapatinib
CAS Number: 231277-92-2
Molecular Formula: C₂₉H₂₆ClFN₄O₄S
Molecular Weight: Approximately 581.1 g/mol
Chemical Class: 4-Anilinoquinazoline tyrosine kinase inhibitor
Synonyms: GW572016, GW 572016, GSK 572016
PubChem CID: 208908
ChEMBL ID: CHEMBL554
DrugBank ID: DB01259
Lapatinib is an intracellular tyrosine kinase inhibitor that inhibits the kinase domains of both EGFR (ErbB1) and HER2 (ErbB2). FDA information reports estimated apparent inhibition constants of approximately 3 nM for EGFR and 13 nM for HER2.
By inhibiting receptor phosphorylation, Lapatinib interferes with downstream ErbB signaling and inhibits ErbB-driven tumor-cell growth in experimental models.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Lapatinib API quality evaluation may include identity, assay, chromatographic purity, related substances, residual solvents, water content, residue on ignition, elemental impurities and other parameters according to the applicable product specification.
The exact analytical acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Lapatinib is an antineoplastic tyrosine kinase inhibitor used in oncology. It has been used in treatment regimens for certain HER2-positive breast cancers, including in combination with other anticancer therapies according to applicable prescribing information.
The specific approved indication, dosage form and combination regimen should always be confirmed against the regulatory requirements applicable to the intended market.
Lapatinib is a defined synthetic small molecule with molecular formula C₂₉H₂₆ClFN₄O₄S and molecular weight approximately 581.1 g/mol.
Lapatinib itself should be distinguished from Lapatinib Ditosylate Monohydrate. Lapatinib Ditosylate Monohydrate has CAS 388082-78-8 and molecular weight approximately 943.5 g/mol.
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and other documentation should be confirmed with MEDIOCON INC according to the intended application and customer requirements.
| Parameter | Specification |
|---|---|
| Appearance | Yellow solid |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Lapatinib API Manufacturer and Supplier in India (CAS 231277-92-2) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Lapatinib API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance